GRI Bio to Present at A.G.P.'s Annual Healthcare Company Showcase
GRI Bio (NASDAQ: GRI), a biotechnology company focused on developing Natural Killer T (NKT) cell modulators for inflammatory, fibrotic and autoimmune diseases, announced its participation in A.G.P.'s Annual Healthcare Company Showcase. CEO Marc Hertz, PhD will engage in a fireside chat on Wednesday, May 21, 2025, at 2:40 PM ET. The virtual event will be accessible via webcast through the Events page in the Investors section of GRI Bio's website.
GRI Bio (NASDAQ: GRI), un'azienda biotecnologica specializzata nello sviluppo di modulatori delle cellule Natural Killer T (NKT) per malattie infiammatorie, fibrotiche e autoimmuni, ha annunciato la sua partecipazione all'Annual Healthcare Company Showcase di A.G.P. Il CEO Marc Hertz, PhD parteciper脿 a una conversazione informale il mercoled矛 21 maggio 2025, alle 14:40 ET. L'evento virtuale sar脿 disponibile in webcast attraverso la pagina Eventi nella sezione Investitori del sito web di GRI Bio.
GRI Bio (NASDAQ: GRI), una empresa biotecnol贸gica centrada en el desarrollo de moduladores de c茅lulas Natural Killer T (NKT) para enfermedades inflamatorias, fibr贸ticas y autoinmunes, anunci贸 su participaci贸n en la Presentaci贸n Anual de Empresas de Salud de A.G.P. El CEO Marc Hertz, PhD participar谩 en una charla informal el mi茅rcoles 21 de mayo de 2025, a las 2:40 PM ET. El evento virtual estar谩 disponible v铆a webcast a trav茅s de la p谩gina de Eventos en la secci贸n de Inversores del sitio web de GRI Bio.
GRI Bio (NASDAQ: GRI)电� 鞐检靹�, 靹湢頇� 氚� 鞛愱皜氅挫棴 歆堩櫂鞚� 鞙勴暅 雮挫稊霟� 韨煬 T(NKT) 靹疙彫 臁办爤鞝� 臧滊皽鞐� 欤茧牓頃樀鐢 靸濍獏瓿淀暀 須岇偓搿�, A.G.P.鞚� 鞐半 項姢旒�鞏� 須岇偓 靽检紑鞚挫姢鞐� 彀胳棳頃滊嫟瓿� 氚滍憸頄堨姷雼堧嫟. CEO Marc Hertz, PhD电� 2025雲� 5鞗� 21鞚� 靾橃殧鞚� 鞓ろ泟 2鞁� 40攵�(霃欕秬鞁滉皠)鞐� 韺岇澊鞏挫偓鞚措摐 毂勴寘鞐� 彀胳棳頃� 鞓堨爼鞛呺媹雼�. 臧�靸� 頄夓偓电� GRI Bio 鞗轨偓鞚错姼 韴瀽鞛� 靹轨厴 雮� 鞚措菠韸� 韼橃澊歆�毳� 韱淀暣 鞗轨簮鞀ろ姼搿� 鞁滌箔頃� 靾� 鞛堨姷雼堧嫟.
GRI Bio (NASDAQ : GRI), une entreprise biotechnologique sp茅cialis茅e dans le d茅veloppement de modulateurs des cellules Natural Killer T (NKT) pour les maladies inflammatoires, fibrosantes et auto-immunes, a annonc茅 sa participation 脿 la pr茅sentation annuelle des entreprises de sant茅 d'A.G.P. Le PDG Marc Hertz, PhD participera 脿 une discussion informelle le mercredi 21 mai 2025 脿 14h40 ET. L'茅v茅nement virtuel sera accessible en webcast via la page 脡v茅nements dans la section Investisseurs du site web de GRI Bio.
GRI Bio (NASDAQ: GRI), ein Biotechnologieunternehmen, das sich auf die Entwicklung von Natural Killer T (NKT)-Zellmodulatoren f眉r entz眉ndliche, fibrotische und Autoimmunerkrankungen spezialisiert hat, gab seine Teilnahme an der A.G.P. Annual Healthcare Company Showcase bekannt. CEO Marc Hertz, PhD wird an einem Fireside-Chat am Mittwoch, den 21. Mai 2025, um 14:40 Uhr ET teilnehmen. Die virtuelle Veranstaltung wird 眉ber einen Webcast auf der Veranstaltungsseite im Investor-Bereich der GRI Bio-Website zug盲nglich sein.
- None.
- None.
Live webcast fireside chat with Marc Hertz, PhD, Chief Executive Officer on Wednesday, May 21st at 2:40 PM ET
LA JOLLA, CA, May 16, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: GRI) (鈥淕RI Bio鈥� or the 鈥淐ompany鈥�), a biotechnology company advancing an innovative pipeline of Natural Killer T (鈥淣KT鈥�) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that Marc Hertz, PhD, Chief Executive Officer of GRI Bio will participate in a fireside chat at being held virtually on Wednesday, May 21, 2025 at 2:40 PM ET.
Click to register for the event. A live webcast of the fireside chat will be accessible on the page under the section of the Company鈥檚 website ().
About GRI Bio, Inc.
GRI Bio is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. GRI Bio鈥檚 therapies are designed to target the activity of Natural Killer T (鈥淣KT鈥�) cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. NKT cells are innate-like T cells that share properties of both NK and T cells and are a functional link between the innate and adaptive immune responses. Type I invariant NKT (鈥渋NKT鈥�) cells play a critical role in propagating the injury, inflammatory response, and fibrosis observed in inflammatory and fibrotic indications. GRI Bio鈥檚 lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis, a serious disease with significant unmet need. The Company is also developing a pipeline of novel type 2 diverse NKT (鈥渄NKT鈥�) agonists for the treatment of systemic lupus erythematosus. Additionally, with a library of over 500 proprietary compounds, GRI Bio has the ability to fuel a growing pipeline.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
FAQ
What is GRI Bio's main focus in drug development?
When is GRI Bio's presentation at A.G.P.'s Healthcare Company Showcase?
How can investors access GRI Bio's presentation at A.G.P.'s Healthcare Showcase?
Who will be presenting for GRI Bio at the A.G.P. Healthcare Showcase?
